Corrects name of unit in headline, paragraphs 1 and 4 to biosciences and diagnostic solutions from life sciences. The error also appeared in an earlier version of the story
Feb 5 (Reuters) - Becton Dickinson BDX.N beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device maker aims to focus on its core business.
"We believe the separation will position New BD as a differentiated MedTech leader and enable optimized investment," said CEO Tom Polen.
The company expects to announce more details on the separation plans by the end of fiscal 2025.
Becton's biosciences and diagnostic solutions unit makes diagnostic products such as those used to detect infectious diseases and cancers.
Earlier this week, the Financial Times reported activist investor Starboard Value had taken a stake in Becton and was pushing the company to sell its life sciences unit.
The company also raised the lower end of its fiscal 2025 profit forecast to a range of $14.30 to $14.60 per share, compared to the previous range of $14.25 to $14.60 each.
Becton's total sales for the reported quarter came in at $5.17 billion, above analysts' estimates of $5.1 billion, according to data compiled by LSEG.
On an adjusted basis, the company reported a per-share profit of $3.43, beating analysts' average expectation of $2.98.
(Reporting by Kamal Choudhury, Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Alan Barona)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.